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Introduction
Mediterranean diet includes a number of different nutritional
habits, although some common key elements can be recognized
in dietary patterns of Mediterranean populations: high consump-
tion of fruit, both fresh and dried (e.g. ﬁgs, raisin); raw and cooked
seasonal vegetables; whole-cereal products; ﬁsh and seafood;
dairy products, goat and ewe milk in fermented forms of cheese
and yoghurt; nuts; lean meat such as rabbit and chicken; aromatic
herbs and spices; extra-virgin oliveoil as main dressing; moderate
alcohol drinking, particularly based on red wine. However, in the
southern Mediterranean region, due to cultural and religious
reasons, wine is usually replaced with black tea as a main source
of phytochemicals, mainly polyphenols. The particular structure
and composition of traditional Mediterranean diets, besides their
variety and assortment, have been proposed to explain the low
prevalence of cardiovascular diseases and the improved life
expectancy in some countries which face Mediterranean sea
basin (Iriti and Vitalini, 2012).
Even if wine is an alcoholic beverage, a plethora of
beneﬁcial biological and pharmacological activities has been
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Since decades, it has been suggested that regular, moderate consumption of red wine, a
major component of Mediterranean diet, at main meals, may contribute to explain the
healthy properties attributed to this traditional dietary style. Despite preclinical in vitro/
in vivo data have shown a signiﬁcant cardioprotective activity of grape phytochemicals,
mostly polyphenols, evidence in humans is still debated. This lack of consensus may be due
to the equilibrium between the two main components of wine relevant for health: ethanol
and bioactive compounds or phytochemicals, which include not only polyphenols, but also
newly detected molecules, such as melatonin and phytosterols. The state of art related to
this delicate equilibrium represents the starting point for designing future clinical trials, in
perspective of clinical recommendations. A better comprehension of the wine chemistry
complexity with its major components embodies a pivotal issue in biomedicine, involving
the ﬁelds of diet-related environmental medicine as well as chronomedicine. In this paper,
we brieﬂy reviewed putative beneﬁcial effects of moderate red wine intake in humans,
focusing on the reduction of cardiovascular risk.
# 2014 Faculty of Health and Social Studies, University of South Bohemia in Ceske
Budejovice. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
* Corresponding author at: via G. Celoria 2, 20133 Milan, Italy. Tel.: +39 0250316766; fax: +39 0250316781.
E-mail address: marcello.iriti@unimi.it (M. Iriti).
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/jab
1214-021X/$ – see front matter # 2014 Faculty of Health and Social Studies, University of South Bohemia in Ceske Budejovice. Published
by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
http://dx.doi.org/10.1016/j.jab.2014.09.003
Author's personal copy
ascribed, in the past decades, to some grape and wine
metabolites, under the name of ‘‘bioactive compounds’’. In
particular, polyphenols, a large group of phenylalanine
derivatives, have been extensively investigated. These phy-
tochemicals, divided into ﬂavonoids (including anthocyanins),
stilbenes (e.g. resveratrol) and proanthocyanidins (or con-
densed tannins) (Figs. 1 and 2), possess different molecular
and biochemical targets both in healthy and diseased cells
(Iriti and Faoro, 2009). Their main mechanisms of (cardio)
protection include high antioxidant and antiinﬂammatory
activities; resveratrol, in particular, has been reported to
stimulate endothelial production of nitric oxide, reducing
oxidative stress, decreasing vascular inﬂammation and pre-
venting platelet aggregation (Li and Förstermann, 2012).
Furthermore, the diversity of grape and wine chemistry has
been recently improved by the discovery of new bioactive
molecules in these products, i.e. melatonin and phytosterols
(Figs. 2 and 3). Melatonin is an indoleamine traditionally
considered a vertebrate neurohormone, secreted from the
pineal gland with a circadian rhythm, and signiﬁcantly present
in grapevine products (Vitalini et al., 2013). It plays a pivotal
role in human chronobiology, since it regulates the biological
clock and circadian physiological functions, such as sleep and
appetite (Rodella et al., 2013). On what concern cardiovascular
protection, melatonin has been shown to improve blood
pressure parameters as suggested by the results of a meta-
analysis (Grossman et al., 2011), not only acting on heart with a
central effect, but also by reducing vessel oxidation, nitric
oxide metabolism and improving endothelial functions (Cicero
and Borghi, 2013).
In addition to melatonin, three phytosterols, i.e. b-
sitosterol, stigmasterol and campesterol, effective hypocho-
lesterolizing agents, have been detected in grapes and wine
(Ruggiero et al., 2013). Phytosterols have been reported to play
a key role against dyslipidemias, with hypocholesterolemic
effects: daily intake of plant sterols or stanols of 1.6–2.0 g/day
is able to decrease intestinal cholesterol absorption from the
gut by about 30%, as well as plasma total and LDL cholesterol
levels, thus reducing the cardiovascular risk (Marangoni and
Poli, 2010). Therefore, it can be hypothesized that these and,
possibly, other phytochemicals may maximize the healthy
properties of polyphenols by additive and/or synergistic
effects.
Despite polyphenols are considered the archetype of health
beneﬁts attributed to a moderate red wine consumption, as
demonstrated by a huge amount of in vitro/in vivo experimental
models (Iriti and Faoro, 2009), the in human evidence is still
inconclusive, possibly because of the presence of ethanol in
wine, which can counteract or nullify, to some extent, the
protective effects of polyphenols in conditions of heavy or
binge (episodic heavy) wine intake (Barbero-Becerra et al.,
2011). As an example, despite a vast preclinical literature on
resveratrol, clinical evidence on its cardioprotective potential
is still largely open to doubt (Cicero and Borghi, 2013).
Fig. 1 – Typical bioactive polyphenols present in red wine include anthocyanidins (malvidin), stilbenes (resveratrol), flavonols
(quercetin), flavan-3-ols [(+)-catechin] and proanthocyanidins or condensed tannins, oligo- and polymeric derivatives of
flavan-3-ol units.
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In this perspective, to date, the equilibrium between
ethanol and bioactive phytochemicals contained in wine is
under discussion, involving those biomedicine-related studies
exploring effects of diet on disease development and preven-
tion (Berger, 2011).
In this review, we brieﬂy examined the health-promoting
effects of moderate red wine intake in humans, focusing on
the suggested association with cardiovascular protection. We
focused on studies which compared wine and spirit consump-
tion, with strongly different ethanol/phytochemicals ratios.
Meta-analyses on wine and cardiovascular disease were also
considered. Our work aims to provide an updated knowledge
on this issue in order to stimulate and encourage future
biomedical research, mainly in the ﬁeld of diet-related
environmental medicine and of chronobiology as well.
Interventional studies
Several in humans studies have been recently carried out to
elucidate the relation among types of alcoholic beverage (wine,
spirit, beer), under different drinking patterns, and cardiovas-
cular risk. Interventional studies investigated effects on
surrogate outcomes, mainly serum biomarkers and functional
changes.
Variation of serum biomarkers
The different effects of red wine and gin consumption on
inﬂammatory biomarkers of atherosclerosis were investigated
in a randomized, crossover, single-blinded clinical trial. Forty
healthy men (mean age 37.6 years) consumed 30 g of ethanol
per day, for 28 days, as either red wine (two 160 mL glasses) or
gin (100 mL), the latter a beverage with a very low polyphenol
content. Blood sample analyses indicated that both wine and
gin drinking had anti-inﬂammatory effects by reducing
plasma ﬁbrinogen (by 9 and 5%, respectively) and cytokine
interleukin-1a (IL-1a) (by 21 and 23%, respectively) levels.
However, only wine had two additional effects: (i) a 21%
decrease in C-reactive protein (CRP); (ii) a reduction of
monocyte and endothelial adhesion molecules including very
late activation antigen 4 (VLA-4) (32%), monocyte chemoat-
tractant protein (MCP-1) (46%), soluble vascular cell adhesion
molecule-1 (VCAM-1) (17%) and intercellular adhesion
molecule-1 (ICAM-1) (-9%) (Estruch et al., 2004). Similarly, 4-
week supplementation of red wine decreased plasma ﬁbrino-
gen levels in 15 healthy male volunteers, who were instructed
to drink 250 mL/day of this beverage (12% alcohol, 1.2 g/L total
polyphenols, 0.64 g/L total anthocyanins and 1.0 g/L total
proanthocyanidins). However, the authors also found an
increase of mean platelet volume and serum levels of
inﬂammatory and endothelial cell activation markers, as
ICAM-1, E-selectin and IL-6 (Tozzi Ciancarelli et al., 2011). On
the other hand, 150 mL/day of red wine (15 g/day of alcohol) for
3 weeks failed to reduce serum CRP levels and only slightly
decreased ﬁbrinogen concentrations in 87 Norwegian healthy
volunteers 35–70 years old (mean age 50.0 years) (Retterstol
et al., 2005).
In another randomized, crossover clinical trial, 20 g/day of
ethanol as red or white wine (1 glass of 100 mL at lunch and
dinner) were administered to 35 healthy women aged 20–50
years (mean age 38.0 years) for 4 weeks. Both wines reduced
serum biomarkers of inﬂammation and endothelial activation
in subjects, even if anti-inﬂammatory effects associated with
moderate red wine consumption were higher than those
produced by white wine, probably because of a different
polyphenol content (Sacanella et al., 2007).
The moderate intake of red wine or an alcoholic beverage
with a very low polyphenol content was investigated in terms
of inﬂuence on serum antioxidant vitamins, antioxidant
status, lipid proﬁle and oxidability of low-density lipoprotein
Fig. 2 – Presence of main polyphenols (anthocyanins,
resveratrol and proanthocyanidins), phenolic acids
(hydroxycinnamates) and new phytochemicals
(phytosterols and melatonin) in grape berry and seed
tissues.
Fig. 3 – Recently discovered bioactive phytochemicals in
wine are indoleamines (melatonin) and phytosterols (b-
sitosterol, stigmasterol and campesterol).
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(LDL) particles. Forty healthy men aged 30–50 years (mean age
38.0 years) received 30 g of ethanol per day as red wine (two
160 mL glasses at dinner) or gin (100 mL at dinner), for 28 days.
In particular, compared to gin intervention, wine intake
reduced plasma superoxide dismutase (SOD) activity, mal-
ondialdehyde (MDA) and oxidized LDL levels (Estruch et al.,
2011).
By a similar study design (a randomized, crossover clinical
trial), the same authors also demonstrated that red wine
exerted higher protective effects on glucose metabolism and
lipid proﬁle than other alcoholic beverages. Sixty-seven men
aged 55–75 years were instructed to consume gin (100 mL/day,
containing 30 g of ethanol), red wine (272 mL/day, containing
30 g of ethanol and 798 mg of total polyphenols), or de-
alcoholized red wine (272 mL/day, containing 1.14 g of ethanol
and 733 mg of total polyphenols) for 4 weeks. Participants were
at high cardiovascular risk, reporting family history of
premature cardiovascular disease and/or presence of diabetes,
hypertension, dyslipidemia and overweight/obesity. Plasma
insulin and insulin resistance decreased after interventions
with both wines; high-density lipoprotein (HDL)-cholesterol,
apolipoprotein (Apo)A-1 and ApoA-2 increased after red wine
and gin administration. On the other hand, only red wine
reduced lipoprotein plasma concentrations (Chiva-Blanch
et al., 2013a). In another study, the same authors showed
that both ethanol and non-alcoholic components of red wine
may regulate soluble inﬂammatory mediators in high-cardio-
vascular risk patients, whereas only phenolic compounds may
modulate leukocyte adhesion molecules (Chiva-Blanch et al.,
2012a). De-alcoholized red wine also decreased systolic and
diastolic blood pressures in patients at high cardiovascular
risk, and these variations correlated with increased concen-
tration of plasma nitric oxide (NO) (a potent vasodilator)
(Chiva-Blanch et al., 2012b).
The relationship between body mass index (BMI) and
plasma triglycerides was investigated in 42 Brazilian individ-
uals (64% men, mean age 46.0 years, mean BMI 25.13 kg/m2)
consuming 250 mL/day of red wine at meals for 2 weeks. In
general, red wine increased plasma levels of triglycerides and
the triglycerides/HDL-cholesterol ratio. When subjects were
divided into three categories, according to their BMI, the
authors reported that individuals with higher BMI, although
non obese, were at higher risk for elevation in plasma
triglycerides and the triglycerides/HDL-cholesterol ratio after
short-time red wine consumption (Cesena et al., 2011).
Possible prebiotic effects associated with red wine intake
were recently suggested. Ten healthy male volunteers
received red wine (272 mL/day), de-alcoholized red wine
(272 mL/day) or gin (100 mL/day) for 20 days. Total fecal
DNA analysis by real-time qPCR revealed that, compared with
baseline, daily consumption of red wine polyphenols signiﬁ-
cantly increased the number of Enterococcus, Prevotella, Bacter-
oides, Biﬁdobacterium, Bacteroides uniformis, Eggerthella lenta, and
Blautia coccoides–Eubacterium rectale groups. In parallel, systolic
and diastolic blood pressures, triglyceride, total cholesterol,
HDL-cholesterol and CRP concentrations decreased signiﬁ-
cantly. Besides promoting the growth of probiotic bacteria, red
wine polyphenols also inhibited pathogenic bacteria in the
human microbiota, such as Clostridium spp (Queipo-Ortuño
et al., 2012).
As previously mentioned, health beneﬁts of moderate wine
consumption have, at least in part, been attributed to grape
polyphenols. Protection against oxidative damage of a
Mediterranean diet compared with a western (US) diet, with
or without the concomitant intake of red wine, was assessed in
42 young adults (20–27 years old). Volunteers were randomly
assigned to either the Mediterranean diet group or the western
diet group for 3 months and, only during the second month,
they received 240 mL/day of red wine. Mediterranean diet
increased plasma vitamin C and b-carotene levels and total
antioxidant activity, while western diet raised only vitamin E
content. Wine supplementation, analyzed combining both
diet groups, increased: (i) plasma vitamin C, b-carotene and
uric acid concentrations and total antioxidant activity; (ii)
plasma and urinary total polyphenols and (iii) red blood cell
glutathione levels, while decreasing plasma vitamin E and
glutathione contents. Western diet group also showed higher
concentrations of 8-hydroxy-20-deoxyguanosine (8-OHdG, a
marker of oxidative DNA damage), in DNA of peripheral blood
leukocytes, and plasma nitrotyrosine (a marker of oxidative
protein damage) when compared with Mediterranean diet
group. Wine intake signiﬁcantly reduced 8-OHdG and plasma
nitrotyrosine in both diets, particularly in the western group.
The authors concluded that moderate red wine consumption
counteracted the oxidative damage caused by western diet
(Urquiaga et al., 2010).
Furthermore, ever if on few participants, it was shown that
300 mL/day of alcohol-free red wine for 1 week increased the
activities of antioxidant enzymes (superoxide dismutase,
catalase and glutathione reductase) in 8 volunteers aged 25–
40 (mean age 28.0) following a low phenolic diet (Noguer et al.,
2012). However, despite a general consensus attributing
antioxidant beneﬁts to sustained wine consumption in
healthy volunteers, Covas and colleagues concluded, in a
review paper, that there is no evidence, at present, that
supports as wine consumption is associated with antioxidant
beneﬁts other than to counteract a possible prooxidant effect
of the ethanol. On the contrary, data on the antioxidant
protective effects of red wine in conditions of oxidative stress
are promising (Covas et al., 2010). These conclusions are
consistent with our recent results showing that red wine
drinking was not associated to a reduced salivary antiradical
capacity, which, conversely, was greatly improved by the
intake of a capsule of red wine extract (Varoni et al., 2013).
Finally, perspectives of a moderate red wine intake in
secondary prevention of cardiovascular diseases were evalu-
ated. Thirty-nine post myocardial infarct patients (32 men and
7 women, mean age 65.0) were divided into 2 groups: 'red wine
drinkers', administered with 250 mL/day of red wine (3.81 g/L
total polyphenols) at main meals for 2 weeks, and 'water
drinkers'. During this period, all subjects received a 'western
prudent' diet, inspired by the Mediterranean diet principles.
Moderate red wine intake reduced total cholesterol and LDL-
cholesterol, and improved erythrocyte membrane ﬂuidity
(Riﬂer et al., 2012).
Functional changes
Hypertension and blood pressure variations can be considered
useful indirect indicators to analyze a potential protective
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effect of wine against cardiovascular diseases. In terms of
alcohol intake, an increase of the risk of hypertension has been
reported with a regular drinking pattern, in a dose-dependent
manner (Taylor et al., 2009), or with consumption outside
meals, independently from the ethanol amount (Stranges
et al., 2004), while a moderate intake of alcohol appeared not to
affect blood pressure in a normotensive population (Okubo
et al., 2001). As Chiva-Blanch et al. pointed out, diverse effects
of different alcoholic beverages on blood pressure can be
mainly related to their different polyphenol content (Chiva-
Blanch et al., 2013b), as shown on high cardiovascular risk
subjects, where moderate alcohol consumption, in the form of
gin or red wine, did not affect blood pressure, differently from
de-alcoholized red wine which reduced this parameter (Chiva-
Blanch et al., 2012b).
Atrial ﬁbrillation is a less common, but relevant risk factor
exposing patient to cardiovascular events. In a meta-analysis
focusing on high risk populations already affected by
cardiovascular events, a slight/moderate alcohol intake (5–
25 g/day) was signiﬁcantly associated with a lower incidence of
secondary cardiovascular and all-cause mortalities, while
long-term moderate alcohol consumption was related to the
development of these conditions: the authors recommended
to avoid alcohol consumption in these patients (Costanzo
et al., 2010).
Genetic variations
1B gene (ADH1B) encodes for alcohol dehydrogenase (ADH),
the enzyme representing the ﬁrst step of ethanol metabolism
(Edenberg, 2007); a single nucleotide polymorphism
(rs1229984) has been recently associated with low levels of
alcohol consumption and blood ethanol and with reduced risk
of alcohol dependence among drinkers (Yokoyama et al., 2014).
Based on a very large sample (260,000 participants), a recent
study reported that carriers of the A-allele had slight lower risk
of ischemic stroke with an odds ratio of 0.83 (Kato et al., 2011;
Drogan et al., 2012; Lawlor et al., 2013; Holmes et al., 2014). In
particular, Holmes and coworkers identiﬁed relation between
carriers of this allele and cardiovascular traits (non-HDL
cholesterol, interleukin 6 and C reactive protein) including
coronary heart disease (Holmes et al., 2014). These data are
consistent with Asian studies on the rs671 genetic variant of
the aldehyde dehydrogenase 2 gene (ALDH2), enzyme with a
reduced ability to detoxify ethanol and related negative effects
on blood pressure, body mass index and non-HDL cholesterol
levels (Kato et al., 2011; Lawlor et al., 2013).
Observational studies
The beneﬁcial properties of red wine are known since more
than three decades. In 1979, St. Leger and colleagues ﬁrst
described a signiﬁcant inverse relationship between wine
consumption and risk of death from coronary heart disease
(St. Leger et al., 1979). More recently, evidence of a health-
promoting effect of red wine on cardiovascular health
emerged from many epidemiological studies. In a prospective
study, Djoussé and collaborators investigated the association
between alcohol consumption and both risk and mortality for
cardiovascular diseases in 26,399 ('non-Mediterranean') parti-
cipants from the Women's Health Study, with a mean follow-
up of 12.2 years. As compared with abstainers, alcohol intake
of 5–15 g/day was associated with 26%, 35% and 51% lower risk
of cardiovascular disease, total mortality and cardiovascular
disease-related mortality, respectively. In moderate drinkers,
86% of reduced cardiovascular disease risk was explained by
effects on lipids, glucose metabolism, inﬂammatory/haemo-
static factors and blood pressure. Furthermore, no differential
association for beverage type, i.e. beer, wine or spirits, and
studied outcomes was observed by the authors (Djoussé et al.,
2009). Similarly, in a cohort (N = 31,367) of US adult men from
the prospective Aerobic Center Longitudinal Study, ≤6 drinks/
week reduced the risk of cardiovascular disease mortality of
about 29%. When alcohol consumption was stratiﬁed by type
(wine, beer and liquor), no difference was observed (Howie
et al., 2011).
In a large French population, the urban Paris-Ile-De-France
Cohort, composed of 149,773 subjects (97,406 men and 52,367
women with a mean age of 47.6  15 and 47.0  12 years,
respectively), relationship between alcohol intake and cardio-
vascular risk was investigated. The subjects were divided into
four groups according to alcohol consumption: never, low
(<10 g/day), moderate (10–30 g/day) and high (>30 g/day). With
the exception of the subgroup of young subjects (<30 years of
age), alcoholic beverages mainly consisted of wine. In addition,
wine consumption increased with age, whereas those of beer
and appetizers decreased. Moderate alcohol drinkers showed
more favorable clinical and biological proﬁles associated with
lower cardiovascular risk factors, including low BMI, waist
circumference, heart rate, blood pressure, fasting triglycerides,
fasting glucose, plasma LDL-cholesterol and high levels of
plasma HDL-cholesterol (Hansel et al., 2010).
The Italian Longitudinal Study on Aging is a cross-sectional
multi-center study on 1896 men aged 65–84 years, mainly
moderate wine consumers (98%) as a lifelong habit. Partici-
pants were divided into six alcohol consumption groups:
lifelong abstainers, ≤12 g/day, 13–24 g/day, 25–47 g/day, 48–
96 g/day and >96 g/day. Among drinkers, mean daily intakes of
alcohol from wine, beer and spirits were 26.7 g/day, 0.6 g/day
and 3.8 g/day, respectively. Long-lasting moderate drinkers
showed lower levels of systemic inﬂammatory markers, better
hematological parameters and safer metabolic and glycemic
proﬁles. In particular, moderate alcohol consumption in older
age was associated to lower values of ﬁbrinogen and insulin
resistance, and higher levels of HDL-cholesterol and ApoA-1
lipoprotein, even if this pattern of drinking was also associated
with higher LDL-cholesterol and systolic blood pressure
(Perissinotto et al., 2010).
The relative importance of the main components of
Mediterranean diet in producing the inverse association
between increased adherence to this dietary style and all-
cause mortality was investigated in the Greek segment of the
European Prospective Investigation into Cancer and nutrition
(EPIC). The population of this prospective cohort study
consisted of 23,349 men and women, without a previous
diagnosis of cancer, coronary heart disease and diabetes. After
a follow-up of 8.5 years, the contributions of individual
components of Mediterranean diet to this association were
moderate ethanol consumption (23.5%, men >10 g/day and
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<50 g/day, women >5 g/day and <25 g/day, mostly in the form
of wine at main meals), low intake of meat and meat products
(16.6%), high consumption of vegetables (16.2%), fruit and nuts
(11.2%), monounsaturated to saturated lipid ratio (10.6%) and
legumes (9.7%) (Trichopoulou et al., 2009).
The association between alcohol consumption and coro-
nary heart disease was investigated in the Spanish EPIC
cohort. Participants included 15,630 men and 25,808 women
and the median follow-up period was 10 years. Subjects who
reported an alcohol intake higher than 5 g/day at either 20, 30,
40 or 50 years of age, but not during the 12 months prior to
recruitment were categorized as former drinkers. Never-
drinkers were deﬁned as subjects who did not report any
consumption higher than 5 g/day at any age and 0 g/day in the
12 months prior to recruitment. Alcohol intake was classiﬁed
in six categories for men (former drinkers, never-drinkers, low
ethanol intake of 0–5 g/day, moderate ethanol intake of 5–30 g/
day, high ethanol intake of 30–90 g/day and very high ethanol
intake of more than 90 g/day) and ﬁve categories for women
(former drinkers, never-drinkers, low ethanol intake of 0–5 g/
day, moderate ethanol intake of 5–30 g/day and high ethanol
intake of 30–90 g/day). In men aged 29–69 years, moderate,
high and very high ethanol consumptions were associated
with a reduced cardiovascular risk, with a more than 30%
lower incidence of coronary heart disease. This association
was only statistically signiﬁcant in men, probably due to the
low number of coronary heart disease cases in women
(N = 128). The type of alcohol consumed (wine, beer, fortiﬁed
wines) did not affect hazard ratios (Arriola et al., 2010).
The Turkish Adult Risk Factor Study prospectively assessed
the long-term impact of alcohol consumption on different
outcomes, in 3443 men and women (mean age 47.6 years)
included at baseline and followed-up for a mean of 7.4 years.
End-points included overall mortality, coronary heart disease,
diabetes and metabolic syndrome. Daily alcohol intake was
categorized as follows: light drinking, less than 1 drink (1 unit
of alcohol, i.e. 30 mL spirits or 300 mL beer or 120 mL wine);
moderate drinking, 1 to 3 units of alcohol; heavy drinking, >3
units. Heavy alcohol consumption increased the risk for
diabetes, coronary heart disease and, in men, all-cause
mortality and metabolic syndrome, even if without a strong
statistical signiﬁcance. Conversely, moderate intake of alcohol
was not associated with any adverse outcome, but it was
associated to a borderline decrease of cardiovascular risk,
overall mortality and, in women, to a signiﬁcantly lower risk
for metabolic syndrome. Interestingly, 62% of ethanol con-
sumed in Turkey is as beer, more than 30% as spirits and only
5% as wine, a very different drinking pattern compared with
populations of South Europe (Italy, French and Spain), where
wine predominates (Onat et al., 2009).
Association of alcohol consumption and cardiovascular
disease outcomes has been investigated in systematic
reviews and meta-analysis. Data from 84 eligible studies
reported a relative risk (RR), for moderate alcohol drinkers
compared with non-drinkers, of 0.75, 0.71 and 0.75 referring to
cardiovascular disease mortality, incident coronary heart
disease and coronary heart disease mortality, respectively
(Ronksley et al., 2011). In another meta-analysis, a previously
reported J-shaped dose–response relationship between wine
and alcohol consumption and the risk of cardiovascular
events and all-cause mortality was conﬁrmed (Costanzo et al.,
2011). In J-shaped curve, regular and moderate wine drinking, at
the nadir of J, is beneﬁcial, whereas abstinence and heavy
intake, on the short and long arm, respectively, are both
detrimental, though to a different extent (Di Castelnuovo et al.,
2002). A meta-analysis of 34 prospective cohort studies, with
more than 1 million subjects and almost 100,000 death by any
cause, showed a J-shaped association between self-reported
alcohol consumption and mortality (Di Castelnuovo et al., 2006).
Another study reported that the maximum intake of wine at
which protection was still apparent decreased from 72 to 66 or to
41 g/day when either combined fatal and non-fatal vascular
events, or cardiovascular mortality or total mortality were
considered as endpoints, respectively. The minimal doses of
wine at which its maximal protection could be obtained were 21,
24 and 10 g/day for the three respective endpoints (Costanzo
et al., 2011). The same authors described a J-shaped dose-
response curve in patients with cardiovascular risk, with light to
moderate alcohol consumption (5–25 g/day) signiﬁcantly asso-
ciated with a lower incidence of cardiovascular and all-cause
mortalities (Costanzo et al., 2010).
Finally, a meta-analysis of interventional studies was also
carried out. The effects of alcohol consumption on 21
biomarkers associated with the risk of coronary heart disease
were investigated in adults without known cardiovascular
disease. Alcohol signiﬁcantly increased the levels of HDL-
cholesterol, ApoA-1 and adiponectin, but a dose–response
relation was observed only for alcohol and HDL-cholesterol.
Alcohol decreased ﬁbrinogen levels, but did not affect
triglyceride concentrations. Analyses were stratiﬁed by type
of beverage (wine, beer and spirits), but results were similar
(Brien et al., 2011).
Discussion
Despite the main evidences are related to variations of
surrogate factors or risk factors, such as serum inﬂammatory
mediators or functional studies and thus a conclusive
statement is not completely possible, the polyphenol content
of red wine appears to overcome the (detrimental) effects of
ethanol, at least when considering a regular light to moderate
red wine intake at main meals and not in a high risk
population. Indeed, the balance between these two compo-
nents seems to be greatly dependent on the speciﬁc type of
beverage considered, as noticeable not only in view of wine
over spirits or beer (Estruch et al., 2004, 2011; Chiva-Blanch
et al., 2012a, 2013b), but also by comparing white and red wine,
the latter at higher content of polyphenols (Sacanella et al.,
2007). Noteworthy, the comparison between red wine and de-
alcoholized red wine decreased blood pressure in patients at
high cardiovascular risk (Chiva-Blanch et al., 2012b), excluding
atrial ﬁbrillation.
These ﬁndings can be, at least in part, explained by current
evidences related to wine chemicals, thus we suppose that
beneﬁcial effects of wine on reducing inﬂammatory and
vascular biomarkers could be ascribed not only to phenolic
content, but also to the presence of many other phytochem-
icals, such as melatonin and phytosterols, as recently reported
(Ruggiero et al., 2013; Vitalini et al., 2013). Melatonin protects
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against atherosclerosis-related cardiovascular diseases,
resulting from direct free radical-scavenging activity, indirect
antioxidant properties and anti-inﬂammatory activity (Favero
et al., 2013). Similarly, phytosterols have been reported to
reduce the risk of cardiovascular diseases by inhibiting the
absorption of intestinal cholesterol and re-circulating endog-
enous biliary cholesterol, promoting its excretion (Dhankhar,
2013).
Another additional topic is related to the signiﬁcant
increase of several pre-biotic bacteria after daily consumption
of red wine, associated with a decrease of serum biomarkers of
cardiovascular disease (Queipo-Ortuño et al., 2012). Changes of
bacterial population appear to be caused by wine polyphenols,
increasing gut microbiota energy metabolism which, in turn,
enhances host lipid metabolism and triglyceride clearance
(Queipo-Ortuño et al., 2012).
A further element which strongly affects ethanol vs.
phytochemicals equilibrium can be related to genetic factors
of individuals, on what concerns genetic variants encoding
alcohol metabolizing enzymes (alcohol and aldehyde dehy-
drogenases, AHD and ALDH), resulting in altered exposure to
acetaldehyde, a toxic metabolite of ethanol. If carriers of the
AHD1Brs1229984 A-allele are associated with a more favorable
cardiovascular proﬁle (Holmes et al., 2014), other studies
suggested the association of ALDH2 polymorphism with
higher risk of coronary heart disease than other alleles
(Quertemont and Didone, 2006; Drogan et al., 2012).
On the basis of these results, a regular light to moderate
intake of red wine can be considering beneﬁcial for cardiovas-
cular health. As the matter of facts, during the last decades, the
deﬁnition of ‘‘moderate alcohol consumption’’ changed over
countries, corresponding to a generally decreased amount of
ethanol considered (Chiva-Blanch et al., 2013b).
However, several limitations can be observed throughout
studies above reported, contributing to render decisive
assertions more difﬁcult. Firstly, a great methodological
heterogeneity among different studies can be detected,
resulting not only from the outcomes considered, but also
from the different amounts of ethanol and polyphenols
contained in diverse wines, using different grapes and wine-
making techniques. Their ‘‘equilibrium’’ potentially changes
each time a new type of wine is taken into account. Secondly,
most of works did not investigate the role of a further key
element inﬂuencing the effect of wine on cardiovascular
system: the drinking patterns (Bagnardi et al., 2013b). As
already concluded by Chiva-Blanch and co-workers, heavy
and/or binge alcohol intakes are conﬁrmed to be relevant risk
factors for cardiovascular diseases, while the effect of a light
wine intake remains still controversial (Chiva-Blanch et al.,
2013a,b).
To elucidate this debate, a full comprehension of wine
chemistry as well the role of speciﬁc (class of) compounds will
be pivotal. Biomedicine-related ﬁelds could address to this
topic, investigating ethanol and bioactive components, to
comprehend which constituent predominates. Interestingly,
environmental medicine which explores, among the other
topics, the effects of diet on pathophysiological states, will be
greatly enriched by studies on wine drinking and wine
bioactive phytochemicals, also considering the growing role
of this beverage all over the world (Berger, 2011). Moreover, the
recent ﬁndings concerning the presence of melatonin in wine
would open a new ﬁeld of biomedical research, i.e. chronobi-
ology (Berger, 2011), with the potential use of dietary
melatonin in regulating circadian rhythms.
In order to clarify whether wine represents an independent
factor for cardiovascular disease, future studies should stratify
investigations by ‘‘unique’’ intake of wine, as alcoholic
beverage. If throughout interventional studies, long-term
wine administration is obviously subjected to many ethical
restrictions, both in healthy and diseased subjects, observa-
tional studies need to be correctly interpreted, because of
many bias and confounding factors, in order not to misinter-
pret random effect and cause–effect relationship. Indeed,
additional risk or protective factors, such as smoking habit or a
diet rich in fruit and vegetables, respectively, could inﬂuence
results, as well as publication bias and the possibility of
incorrect reporting of alcohol consumption, mainly in deﬁning
different drinking patterns.
Conclusions
The studies examined in this survey suggest as red wine may
confer an 'added value' compared to other alcoholic beverages,
particularly spirits (Fig. 4). As regards cardioprotection,
experiments using wine, de-alcoholized wine and spirits, in
conditions of moderate intake, point to health beneﬁts
deriving from polyphenols and, possibly, other bioactive
phytochemicals that may counteract the detrimental effects
of ethanol. On the other hand, because of the positive effects of
low amounts of alcohol on HDL-cholesterol and haemostatic
factors, ethanol and polyphenols may also exert additive and/
or synergistic protective effects on cardiovascular system
(Hansel et al., 2012; Li and Förstermann, 2012).
However, even if results from clinical trials represent the
highest level of evidence in medicine, studies in humans have
some intrinsic and environmental limitations. For interven-
tional studies, wine administration is, obviously, subjected to
many ethical limitations, both in healthy and diseased
subjects. Similarly, observational studies have to be properly
interpreted because of many bias and confounding factors, in
order not to misinterpret random effect and cause–effect
relationship. For instance, Mediterranean populations seem to
be more physically active than the north European counter-
part, even only for climatic conditions. Another example is
related to wine drinkers, which seem to be more health fanatic
than beer or spirit consumers. These aspects may ‘‘confound’’
the scenario where the clinical studies are conducted.
To conclude, we would like to further clarify the issue of
'regular, low to moderate red wine consumption at main
meals'. This sentence indicates that both pattern and amount
and wine intake are relevant. Episodic heavy (or binge)
drinking is considered more harmful that consumption of
less than or equal to 2 drinks per day, but more than 0, for men,
and less than or equal to 1 drink per day, but more than 0, for
women (Stockley, 2012; Chiva-Blanch et al., 2013b). Lastly, red
wine polyphenols, independently from ethanol, reduced the
pro-oxidant effects of a fat-rich meal, thus reducing the
postprandial susceptibility of LDL to oxidation (Natella et al.,
2001).
j o u r n a l o f a p p l i e d b i o m e d i c i n e 1 2 ( 2 0 1 4 ) 1 9 3 – 2 0 2 199
Author's personal copy
Conﬂict of interests
The authors declare no conﬂict of interest.
Acknowledgements
Authors are grateful to their institutions for ﬁnancial support.
r e f e r e n c e s
Arriola, L., Martinez-Camblor, P., Larrañaga, N., Basterretxea, M.,
Amiano, P., Moreno-Iribas, C., Dorronsoro, M., 2010. Alcohol
intake and the risk of coronary heart disease in the Spanish
EPIC cohort study. Heart 96, 124–130.
Barbero-Becerra, V.J., López-Velázquez, J.A., Sánchez-Valle, V.,
Uribe, M., Méndez-Sánchez, N., 2011. Alcohol effects on liver
diseases: good or bad buddy? Ann. Hepatol. 11, 944–948.
Berger, J., 2011. The age of biomedicine: current trends in
traditional subjects. J. Appl. Biomed. 9, 57–61.
Brien, S.E., Ronksley, P.E., Turner, B.J., Mukamal, K.J., Ghali, W.A.,
2011. Effect of alcohol consumption on biological markers
associated with risk of coronary heart disease: systematic
review and meta-analysis of interventional studies. BMJ 342,
d636.
Cesena, F.H.Y., Coimbra, S.R., Andrade, A.C.M., da Luz, P.L., 2011.
The relationship between body mass index and the variation
in plasma levels of triglycerides after short-term red wine
consumption. J. Clin. Lipidol. 5, 4–8.
Chiva-Blanch, G., Urpi-Sarda, M., Llorach, R., Rotches-Ribalta,
M., Guillén, M., Casas, R., Arranz, S., Valderas-Martinez, P.,
Portoles, O., Corella, D., Tinahones, F., Lamuela-Raventos, R.
M., Andres-Lacueva, C., Estruch, R., 2012a. Differential effects
of polyphenols and alcohol of red wine on the expression of
adhesion molecules and inﬂammatory cytokines related to
atherosclerosis: a randomized clinical trial. Am. J. Clin. Nutr.
95, 326–334.
Chiva-Blanch, G., Urpi-Sarda, M., Ros, E., Arranz, S., Valderas-
Martínez, P., Casas, R., Sacanella, E., Llorach, R., Lamuela-
Raventos, R.M., Andres-Lacueva, C., Estruch, R., 2012b.
Dealcoholized red wine decreases systolic and diastolic
blood pressure and increases plasma nitric oxide short
communication. Circ. Res. 111, 1065–1068.
Chiva-Blanch, G., Urpi-Sarda, M., Ros, E., Valderas-Martinez, P.,
Casas, R., Arranz, S., Guillén, M., Lamuela-Raventos, R.M.,
Llorach, R., Andres-Lacueva, C., Estruch, R., 2013a. Effects of
red wine polyphenols and alcohol on glucose metabolism
and the lipid proﬁle: a randomized clinical trial. Clin. Nutr.
32, 200–206.
Chiva-Blanch, G., Arranz, S., Lamuela-Raventos, R.M., Estruch,
R., 2013b. Effects of wine, alcohol and polyphenols on
cardiovascular disease risk factors: evidences from human
studies. Alcohol Alcohol. 48, 270–277.
Cicero, A., Borghi, C., 2013. Evidence of clinically relevant
efﬁcacy for dietary supplements and nutraceuticals. Curr.
Hypertens. Rep. 15, 260–267.
Costanzo, S., Di Castelnuovo, A., Donati, M.B., Iacoviello, L., de
Gaetano, G., 2010. Alcohol consumption and mortality in
patents with cardiovascular disease. J. Am. Coll. Cardiol. 55,
1339–1347.
Costanzo, S., Di Castelnuovo, A., Donati, M.B., Iacoviello, L., de
Gaetano, G., 2011. Wine, beer or spirit drinking in relation to
fatal and non-fatal cardiovascular events: meta-analysis.
Eur. J. Epidemiol. 11, 833–850.
Fig. 4 – Cardioprotective effects attributed to proper red wine consumption are due to both alcoholic and polyphenolic
components. Bioactive phytochemicals may also counteract detrimental effects of ethanol. LDL, low-density lipoprotein;
HDL, high-density lipoprotein; Apo A-1, apolipoprotein A-1.
j o u r n a l o f a p p l i e d b i o m e d i c i n e 1 2 ( 2 0 1 4 ) 1 9 3 – 2 0 2200
Author's personal copy
Covas, M.I., Gambert, P., Fitó, M., de la Torre, R., 2010. Wine and
oxidative stress: up-to-date evidence of the effects of
moderate wine consumption on oxidative damage in
humans. Atherosclerosis 208, 297–304.
Dhankhar, J., 2013. Cardioprotective effects of phytosterols. Int.
J. Pharm. Sci. Res. 4, 590–596.
Di Castelnuovo, A., Rotondo, S., Iacoviello, L., Donati, M.B., de
Gaetano, G., 2002. Meta-analysis of wine and beer
consumption in relation to vascular risk. Circulation 105,
2836–2844.
Di Castelnuovo, A., Costanzo, S., Bagnardi, V., Donati, M.B.,
Iacoviello, L., de Gaetano, G., 2006. Alcohol dosing and total
mortality in men and women: an updated meta-analysis of
34 prospective studies. Arch. Intern. Med. 166, 2437–2445.
Djoussé, L., Lee, I.M., Buring, J.E., Gaziano, J.M., 2009. Alcohol
consumption and risk of cardiovascular disease and death in
women – potential mediating mechanisms. Circulation 120,
237–244.
Drogan, D., Sheldrick, A.J., Schutze, M., Knuppel, S., Andersohn,
F., di Giuseppe, R., Herrmann, B., Willich, S.N., Garbe, E.,
Bergmann, M.M., Boering, H., Weikert, C., 2012. Alcohol
consumption, genetic variants in alcohol deydrogenases,
and risk of cardiovascular diseases: a prospective study and
meta-analysis. PLoS ONE 7, e32176.
Edenberg, H.J., 2007. The genetics of alcohol metabolism: role of
alcohol dehydrogenase and aldehyde dehydrogenase
variants. Alcohol Res. Health 30, 5–13.
Estruch, R., Sacanella, E., Badia, E., Antúnez, E., Nicolás, J.M.,
Fernández-Solá, J., Rotilio, D., de Gaetano, G., Rubin, E.,
Urbano-Marquez, A., 2004. Different effects of red wine and
gin consumption on inﬂammatory biomarkers of
atherosclerosis: a prospective randomized crossover trial:
effects of wine on inﬂammatory markers. Atherosclerosis
175, 117–123.
Estruch, R., Sacanella, E., Mota, F., Chiva-Blanch, G., Antúnez, E.,
Casals, E., Deulofeu, R., Rotilio, D., Andres-Lacueva, C., Lamuela-
Raventos, R.M., de Gaetano, G., Urbano-Marquez, A., 2011.
Moderate consumption of red wine, but not gin, decreases
erythrocyte superoxide dismutase activity: a randomised cross-
over trial. Nutr. Metab. Cardiovasc. Dis. 21, 46–53.
Favero, G., Rodella, L., Reiter, R., Rezzani, R., 2013. Melatonin and
its atheroprotective effects: a review. Mol. Cell. Endocrinol.
382, 926–937.
Grossman, E., Laudon, M., Zisapel, N., 2011. Effect of melatonin
on nocturnal blood pressure: meta-analysis of randomized
controlled trials. Vasc. Health Risk Manage. 7, 577–584.
Hansel, B., Thomas, F., Pannier, B., Bean, K., Kontush, A.,
Chapman, M.J., Guize, L., Bruckert, E., 2010. Relationship
between alcohol intake, health and social status and
cardiovascular risk factors in the urban Paris-Ile-De-France
Cohort: is the cardioprotective action of alcohol a myth? Eur.
J. Clin. Nutr. 64, 561–568.
Hansel, B., Kontush, A., Bruckert, E., 2012. Is a cardioprotective
action of alcohol a myth? Curr. Opin. Cardiol. 27, 550–555.
Holmes, M., Zuccolo, L., Silverwood, R., Guo, Y., Ye, Z., Prieto-
Merino, D., et al., 2014. Association between alcohol and
cardiovascular disease: Mendelian randomisation analysis
based on individual participant data. BMJ 349, g4164.
Howie, E.K., Sui, X., Lee, D.C., Hooker, S.P., Hébert, J.R., Blair, S.N.,
2011. Alcohol consumption and risk of all-cause and
cardiovascular disease mortality in men. J. Aging Res. ID: 805062.
Iriti, M., Faoro, F., 2009. Bioactivity of grape chemicals for human
health. Nat. Prod. Commun. 4, 1–24.
Iriti, M., Vitalini, S., 2012. Health-promoting effects of traditional
Mediterranean diets. Pol. J. Food Nutr. Sci. 62, 71–76.
Kato, N., Takeuchi, F., Tabara, Y., Kelly, T.N., Go, M.J., Sim, X.,
et al., 2011. Meta-analysis of genome-wide association
studies identiﬁes common variants associated with blood
pressure variation in East Asians. Nat. Genet. 43, 531–538.
Lawlor, D.A., Nordestgaard, B.G., Benn, M., Zuccolo, L., Tybjaerg-
Hansen, A., Davey Smith, G., 2013. Exploring causal associations
between alcohol and coronary heart disease risk factors: ﬁndings
from a Mendelian randomization study in the Copenhagen
General Population Study. Eur. Heart J. 34, 2519–2528.
Leger, A.S., Cochrane, A.L., Moore, F., 1979. Factors associated
with cardiac mortality in developed countries with particular
reference to the consumption of wine. Lancet 313, 1017–1020.
Li, H., Förstermann, U., 2012. Red wine and cardiovascular
health. Circ. Res. 111, 959–961.
Marangoni, F., Poli, A., 2010. Phytosterols mad cardiovascular
health. Pharmacol. Res. 61, 193–199.
Natella, F., Ghiselli, A., Guidi, A., Ursini, F., Scaccini, C., 2001. Red
wine mitigates the postprandial increase of LDL susceptibility
to oxidation. Free Radic. Biol. Med. 30, 1036–1044.
Noguer, M.A., Cerezo, A.B., Navarro, E.D., Garcia-Parrilla, M.,
2012. Intake of alcohol-free red wine modulates antioxidant
enzyme activities in a human intervention study.
Pharmacol. Res. 65, 609–614.
Okubo, Y., Suwazono, Y., Kobayashi, E., Nogava, K., 2001.
Alcohol consumption and blood pressure change: 5-year
follow-up study of the association in normotensive workers.
J. Hum. Hypertens. 15, 367–372.
Onat, A., Hergenç, G., Kucukdurmaz, Z., Uğur, M., Kaya, Z., Can,
G., 2009. Moderate and heavy alcohol consumption among
Turks: long-term impact on mortality and cardiometabolic
risk. Turk. Kardiyol. Dern. Ars. 37, 83–90.
Perissinotto, E., Buja, A., Maggi, S., Enzi, G., Manzato, E., Scafato,
E., Mastrangelo, G., Frigo, A.C., Coin, A., Crepaldi, G., Sergi, G.,
2010. Alcohol consumption and cardiovascular risk factors in
older lifelong wine drinkers: the Italian Longitudinal Study
on Aging. Nutr. Metab. Cardiovasc. Dis. 20, 647–655.
Queipo-Ortuño, M.I., Boto-Ordóñez, M., Murri, M., Gomez-
Zumaquero, J.M., Clemente-Postigo, M., Estruch, R., Cardona
Diaz, F., Andés-Lacueva, C., Tinahones, F.J., 2012. Inﬂuence of
red wine polyphenols and ethanol on the gut microbiota
ecology and biochemical biomarkers. Am. J. Clin. Nutr. 95,
1323–1334.
Quertemont, E., Didone, V., 2006. Role of acetaldehyde in
mediating the pharmacological and behavioral effects of
alcohol. Alcohol Res. Health 29, 258–265.
Retterstol, L., Berger, K.E., Braaten, Ø., Eikvar, L., Pedersen, T.R.,
Sandvik, L., 2005. A daily glass of red wine: does it affect
markers of inﬂammation? Alcohol Alcohol. 40, 102–105.
Riﬂer, J.P., Lorcerie, F., Durand, P., Delmas, D., Ragot, K.,
Limagne, E., Mazué, F., Riedinger, J.-M., d'Athis, P., Hudelot,
B., Prost, M., Lizard, G., Latruffe, N., 2012. A moderate red
wine intake improves blood lipid parameters and
erythrocytes membrane ﬂuidity in post myocardial infarct
patients. Mol. Nutr. Food Res. 56, 345–351.
Rodella, L.F., Favero, G., Foglio, E., Rossini, C., Castrezzati, S.,
Lonati, C., Rezzani, R., 2013. Vascular endothelial cells and
dysfunctions: role of melatonin. Front. Biosci. 5, 119–129.
Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J., Ghali, W.A.,
2011. Association of alcohol consumption with selected
cardiovascular disease outcomes: a systematic review and
meta-analysis. BMJ 342, d671.
Ruggiero, A., Vitalini, S., Burlini, N., Bernasconi, S., Iriti, M., 2013.
Phytosterols in grapes and wine, and effects of
agrochemicals on their levels. Food Chem. 141, 3473–3479.
Sacanella, E., Vázquez-Agell, M., Mena, M.P., Antúnez, E.,
Fernández-Solá, J., Nicolás, J.M., Lamuela-Raventos, R.M.,
Ros, E., Estruch, R., 2007. Down-regulation of adhesion
molecules and other inﬂammatory biomarkers after
moderate wine consumption in healthy women: a
randomized trial. Am. J. Clin. Nutr. 86, 1463–1469.
Stockley, C.S., 2012. Is it merely a myth that alcoholic beverages
such as red wine can be cardioprotective? J. Sci. Food Agric.
92, 1815–1821.
j o u r n a l o f a p p l i e d b i o m e d i c i n e 1 2 ( 2 0 1 4 ) 1 9 3 – 2 0 2 201
Author's personal copy
Stranges, S., Wu, T., Dorn, J.M., Freudenheim, J.L., Muti, P.,
Farinaro, E., Russell, M., Nochajski, T.H., Trevisan, M., 2004.
Relationship of alcohol drinking pattern to risk of
hypertension: a population-based study. Hypertension 44,
813–819.
Taylor, B., Irving, H.M., Baliunas, D., Roerecke, M., Patra, J.,
Mohapatra, S., Rehm, J., 2009. Alcohol and hypertension:
gender differences in dose–response relationships
determined through systematic review and meta-analysis.
Addiction 104, 1981–1990.
Tozzi Ciancarelli, M.G., Di Massimo, C., De Amicis, D.,
Ciancarelli, I., Carolei, A., 2011. Moderate consumption of red
wine and human platelet responsiveness. Thromb. Res. 128,
124–129.
Trichopoulou, A., Bamia, C., Trichopoulos, D., 2009. Anatomy of
health effects of Mediterranean diet: Greek EPIC prospective
cohort study. BMJ 338, b2337.
Urquiaga, I., Strobel, P., Perez, D., Martinez, C., Cuevas, A.,
Castillo, O., Marshall, G., Rozowski, J., Leighton, F., 2010.
Mediterranean diet and red wine protect against oxidative
damage in young volunteers. Atherosclerosis 211, 694–699.
Varoni, E.M., Vitalini, S., Contino, D., Lodi, G., Simonetti, P.,
Carrassi, A., Sardella, A., Iriti, M., 2013. Effects of red wine
intake on human salivary antiradical capacity and total
polyphenol content. Food Chem. Toxicol. 58, 289–294.
Vitalini, S., Gardana, C., Simonetti, P., Fico, G., Iriti, M., 2013.
Melatonin, melatonin isomers and stilbenes in Italian
traditional grape products and their antiradical capacity. J.
Pineal Res. 54, 322–333.
Yokoyama, A., Yokoyama, T., Mizukami, T., Matsui, T., Kimura,
M., Matsushita, S., Higuchi, S., Maruyama, K., 2014. Blood
ethanol levels of nonabstinent Japanese alcoholic men in the
morning after drinking and their ADH1B and ALDH2
genotypes. Alcohol Alcohol. 49, 31–37.
j o u r n a l o f a p p l i e d b i o m e d i c i n e 1 2 ( 2 0 1 4 ) 1 9 3 – 2 0 2202
